21-may kuni Amerika Tibbiyot Assotsiatsiyasi jurnalida chop etilgan tadqiqot shuni ko'rsatdiki, o'pka saratoni o'smalarining bir nechta genetik testlari maqsadli terapiya uchun genetik anormalliklarni tanlashga yordam beradi. Maqsadli terapiya olmaydigan bemorlar bilan solishtirganda, o'pka saratoniga mos keladigan terapiya olgan bemorlarning omon qolish muddati uzoqroq bo'ladi. Biroq, ushbu davolash strategiyasi bemorning omon qolishini yaxshilashi mumkinligini tekshirish uchun randomizatsiyalangan klinik sinovlar kerak.
The introduction of targeted therapy has changed the situation of lung cancer treatment by integrating shish genotyping with treatment decisions. adenokarsinoma is the most common type of lung cancer; 130,000 people are diagnosed with lung adenocarcinoma each year in the United States, and 1 million people are diagnosed with lung adenocarcinoma each year worldwide.
Maqolaning asosiy ma'lumotlari shuni ko'rsatadiki, o'pka adenokarsinomasining onkogen drayverlarining faolligi 50% yuqori bo'lishi kutilmoqda va bu haydovchilarning molekulyar anormalliklari saraton rivojlanishi uchun juda muhimdir. Ushbu drayverlar "faol" deb ta'riflanadi, chunki ular genomdagi har bir g'ayritabiiy joyni nishonga olgan dorilarni yo'naltirish orqali salbiy holatga keltirilishi mumkin.
Dr. Mark G. Kris of the Memorial Sloan Kettering Cancer Center in New York et al. counted the frequency of carcinogenic drivers in patients with lung adenocarcinoma, and used this data to explore the proportion of patients who selected a certain targeted treatment together with overall survival . From 2009 to 2012, 14 centers in the O'pka saratoni Mutation Alliance recruited patients with metastatic lung adenocarcinoma and tested tumors in patients who met specific criteria for 10 oncogene driver factors. The study was published in JAMA (2014; doi: 10.1001 / jama.2014.3741).
Tadqiqot davomida tadqiqotchilar 1 bemorning o'simtalarida kamida 1007 genni sinab ko'rdilar va 10 bemorning o'simtalarida 733 ta genni (to'liq genotiplangan bemorlar) sinab ko'rdilar. 733 bemorning 466 nafari (64%) onkogen haydovchini topdi. 275 bemordan 1007 nafari (28%) ushbu natijalardan maqsadli terapiyani tanlash yoki klinik sinovlarga kirish uchun foydalangan.
Onkogen haydovchini olib yurgan va maqsadli dori-darmonlarni qabul qilgan 260 bemorning o'rtacha omon qolish muddati 3.5 yilni tashkil etdi; onkogen haydovchini olib yurgan, ammo maqsadli terapiyadan o'tmagan 318 bemorning o'rtacha omon qolish muddati 2.4 yil; haydovchi topilmagan 360 bemorning o'rtacha omon qolish muddati 2.1 yilni tashkil etdi.
The researchers came to the conclusion that multiple genetic testing can help physicians choose a method of treating o'pka saratoni. Although patients with a certain target drug target driver gene will prolong survival after treatment, the design of this study cannot draw decisive conclusions about the difference in survival caused by oncogene driver.
Manba: Lilak bog'i
